Expansion opportunities Biosearch Technologies Oligo Synthesis operates across three global oligonucleotide manufacturing sites and is actively expanding capabilities and facilities in Europe and North America. This signals potential for sales opportunities around scalable sourcing, custom oligo synthesis capacity, and regional supply chain resilience for NAT and MDx customers amid growth.

Strategic partnerships Recent news shows LGC Group forming partnerships and acquiring related portfolios (Niagen Bioscience assets, ChromaDex Reference Standards) and expanding purification and synthesis capabilities. This indicates a favorable environment for joint offerings, co-developed standards, and integrated nucleic acid chemistry solutions that could complement Biosearch’s oligo synthesis and fluorophore portfolio.

Supply chain security Biosearch emphasizes control over raw materials, including BHQ and proprietary fluorophores, to ensure supply chain security. This positions them well to pitch reliability and risk mitigation to customers in regulated NAT and MDx markets, particularly where consistent supply and traceability are critical.

Technology leverage With a tech stack featuring advanced analytics and cloud collaboration tools (Alteryx, Tableau, Azure, Copilot, SharePoint), there is an opportunity to offer data-driven optimization, QC analytics, and supply chain visibility services to customers developing high-performance nucleic acid products.

Market positioning Operating in the NAT and MDx spaces with multi-site manufacturing and a mid-market revenue range, Biosearch sits between smaller biotech suppliers and large incumbents. This gap lends itself to targeting mid-sized diagnostics developers and contract manufacturers seeking scalable, high-quality oligo synthesis and related chemistry solutions.